Sheffield, United Kingdom
Kynos Therapeutics, founded in 2020, is a UK-based, clinical-stage biopharmaceutical company. The company is carving a niche at the intersection of inflammation, metabolism, and immunity, aligning with its slogan: "Developing first-in-class therapies at the interface of inflammation, metabolism and immunity". As a member of the Falk Group, owned by Dr. Falk Pharma GmbH, Kynos is strategically positioned in the biotechnology, health care, and health and wellness sectors.
The company focuses on novel treatments for acute and chronic inflammatory diseases. Its recent £6.50M Seed Round investment, closed on 07 April 2022, came from prominent investors IP Group, Scottish Enterprise, and Epidarex Capital. These endorsements underscore the confidence in Kynos' potential to advance biopharmaceutical innovations. Investors might see Kynos as a promising player with solid backing and a clear strategic direction in a burgeoning industry.
